Takeda, IDT help manufacture Janssen COVID-19 vaccine

By The Science Advisory Board staff writers

March 15, 2021 -- Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.

Takeda will make manufacturing capacity available at IDT's facilities in Germany and Japan. After three months, the capacity will be returned to Takeda to resume manufacturing for the planned launch of its dengue vaccine, TAK-003, subject to regulatory approvals.

Takeda previously announced that it is partnering with Novavax and Moderna to manufacture and distribute the authorized vaccines in Japan.

Janssen COVID-19 vaccine authorized in EU
Just hours after receiving a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use on March 11,...
Janssen COVID-19 vaccine nearing European approval
Johnson & Johnson announced it has moved a step closer toward marketing authorization for its single-dose COVID-19 vaccine candidate in Europe.
Merck gets $269M to ramp up COVID-19 vaccine manufacturing
Merck has received about $269 million in U.S. funding to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 vaccines and medicines.
Janssen COVID-19 vaccine becomes 3rd authorized in U.S.
Janssen Biotech's COVID-19 vaccine has received an emergency use authorization from the U.S. Food and Drug Administration. The move allows the vaccine...
J&J submits Janssen COVID-19 vaccine to WHO for emergency use listing
Johnson & Johnson announced it has submitted Janssen's investigational single-dose COVID-19 vaccine candidate to the World Health Organization (WHO)...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter